Suven Life Sciences Share Price
378.55+0.20 (+0.05%)
+75.77% past 1 Year
News
Suven Life Sciences completes enrolment in global phase-3 Alzheimer’s trial
Equity
SUVEN
Suven Life Sciences Q1 FY27 loss widens despite modest revenue growth
Equity
SUVEN
Suven Life plans major neuroscience push and Singapore expansion by FY27
Equity
SUVEN
Suven Life Sciences to showcase Alzheimer’s pipeline data at AAIC 2026
Equity
SUVEN
Suven Life Sciences raises Rs 248.84 crores via warrant conversion, adds Singapore unit
Equity
SUVEN
Suven Life Sciences to present CNS pipeline, seek partnerships at BIO 2026
Equity
SUVEN
Suven Life Sciences reports positive topline data for key depression drug trial
Equity
SUVEN
Suven Life Sciences advances key CNS asset after positive Phase-1 data
Equity
SUVEN
Suven Life Sciences presents Samelisant clinical data at SLEEP-2026 meet
Equity
SUVEN
Suven Life Sciences advances global Phase 3 Alzheimer’s agitation trial successfully
Equity
SUVEN
Suven Life Sciences Achieves 76% Enrollment in Phase 3 Trial for Masupirdine in Alzheimer’s Agitation
Equity
SUVEN
Suven Life Sciences Issues 3.17 Cr Equity Shares on Warrant Conversion Raising Rs 425.70 Cr.
Equity
SUVEN
Suven Life Sciences Ltd Reports Q3 Consolidated Net Loss of Rs 102 Crores vs Rs 39.12 Crores YoY.
Equity
SUVEN
Suven Life Sciences hits full enrollment early in key Ropanicant Phase-2b trial
Equity
SUVEN
Suven Life Sciences reports higher Q2 consolidated net loss year-on-year for FY2025-26.
Equity
SUVEN
Sunil Singhania Abakkus Diversified Alpha Fund Acquires 1.32 Percent Stake in Suven Life Sciences Q2
Equity
SUVEN
Suven Life Sciences: Q1 Sl Net Loss 14.80 Crores Rupees Vs Loss 7.70 Crores (Yoy) || Q1 Revenue 1.90 Crores Rupees Vs 1.00 Crores (Yoy)
Equity
SUVEN
Suven Life Sciences - Quaterly Results
Equity
SUVEN
Suven Life Sciences reports Profit after tax of Rs -14.78 Crores, in the June 2025 quarter
Equity
SUVEN
Suven Life Sciences - Quaterly Results
Equity
SUVEN